Orasis Highlights Presbyopia Education Efforts at Vision Source Meeting

A LinkedIn post from Orasis Pharmaceuticals highlights the company’s presence at the VS The Exchange meeting organized by Vision Source, with a focus on presbyopia eye drops and clinical education. The post credits optometrists Jade Coats, O.D., F.A.A.O., and Bobby “Chip” Wood Jr. for addressing misconceptions around presbyopia treatments and emphasizing flexible options for improving near vision.

For investors, the emphasis on practitioner education and myth‑busting around presbyopia drops suggests Orasis is working to strengthen demand drivers and clinical acceptance in the eye‑care community. As presbyopia represents a large and growing patient population, deeper engagement with influential optometrists and networks like Vision Source could help support future product uptake, pricing power, and long‑term revenue potential if Orasis successfully commercializes relevant therapies.

The recognition of Vision Source’s 35‑year milestone also implies Orasis is aligning itself with established distribution and referral channels in optometry. This kind of relationship‑building may enhance the company’s positioning in the competitive presbyopia treatment space, where physician advocacy and education often play a critical role in market penetration and prescription behavior.